

AbbVie Inc

S&P Capital IQ Recommendation



S&P Capital IQ Equity Analyst Jeffrey Loo, CFA

Price

\$52.58 (as of Feb 12, 2016 4:00 PM ET)

12-Mo. Target Price

\$84.00

Report Currency

USD

Investment Style

Large-Cap Growth

GICS Sector Health Care
Sub-Industry Biotechnology

Summary This company is a global research-based pharmaceuticals business that emerged as a separate entity following its spin-off from Abbott Laboratories at the start of 2013. AbbVie's key drug is Humira for rheumatoid arthritis.

Key Stock Statistics (Source S&P Capital IQ, Vickers, company reports)

52-Wk Range	\$71.60– 45.45	S&P Oper. EPS 2016E	5.03	Market Capitalization(B)	\$85.955	Beta	1.66
Trailing 12-Month EPS	\$3.13	S&P Oper. EPS 2017E	5.93	Yield (%)	4.34	S&P 3-Yr. Proj. EPS CAGR(%)	18
Trailing 12-Month P/E	16.8	P/E on S&P Oper. EPS 2016E	10.5	Dividend Rate/Share	\$2.28	S&P Quality Ranking	NR
\$10K Invested 5 Yrs Ago	NA	Common Shares Outstg. (M)	1,634.7	Institutional Ownership (%)	69		

Price Performance



Analyst's Risk Assessment

LOW	MEDIUM	HIGH
------------	---------------	-------------

Our risk assessment reflects common challenges to branded drugs, including competition from generics, pricing restraints and R&D related risks. ABBV is also heavily reliant on one drug -- Humira -- which currently accounts for about 55% of sales. But recently approved Hepatitis C drug, Viekira Pak, should help diversify sales.

Revenue/Earnings Data

Revenue (Million \$)

	1Q	2Q	3Q	4Q	Year
2015	5,040	5,475	5,944	6,400	22,859
2014	4,563	4,926	5,019	5,452	19,960
2013	4,329	4,692	4,658	5,111	18,790
2012	4,173	4,493	4,508	5,206	18,380
2011	--	--	--	--	17,639
2010	--	--	--	--	15,638

Earnings Per Share (\$)

	2015	2014	2013	2012	2011	2010
0.63	0.83	0.74	0.92	3.13		
0.61	0.68	0.31	-0.51	1.10		
0.60	0.66	0.60	0.70	2.56		
0.56	0.80	1.01	0.98	3.35		
--	--	--	--	2.03		
--	--	--	--	--		

Fiscal year ended Dec. 31. Next earnings report expected: Late April. EPS Estimates based on S&P Capital IQ Operating Earnings; historical GAAP earnings are as reported in Company reports.

Dividend Data

Amount (\$)	Date Decl.	Ex-Div. Date	Stk. of Record	Payment Date
0.510	Feb 19	Apr 13	Apr 15	May 15 '15
0.510	Jun 18	Jul 13	Jul 15	Aug 14 '15
0.510	Sep 11	Oct 13	Oct 15	Nov 16 '15
0.570	Oct 30	Jan 13	Jan 15	Feb 16 '16

Dividends have been paid since 2013. Source: Company reports.

Past performance is not an indication of future performance and should not be relied upon as such.

Past performance is not an indication of future performance and should not be relied upon as such.

Analysis prepared by Equity Analyst **Jeffrey Loo, CFA** on Jan 29, 2016 04:54 PM, when the stock traded at **\$54.90**.

Highlights

- In May, ABBV acquired Pharmacyclics for \$21 billion. Pharmacyclics' Imbruvica is approved to treat three types of blood cancers. We see Imbruvica sales of \$1.3 billion in 2016 and \$5 billion in 2020, but we note Imbruvica is co-promoted with Johnson & Johnson (JNJ 102 Buy). This deal gives ABBV an experienced sales force for its own blood cancer drug, Venetoclax, which has FDA breakthrough designation, and a FDA action date in H1 2016.
- We see 2016 sales growing 14.2% to \$26.1 billion on robust sales of Humira for rheumatoid arthritis aided by greater penetration of emerging markets. We expect Humira sales to increase to \$16.0 billion in 2016 from \$14.0 billion in 2015, and see Viekira Pak sales flattening to about \$1.7 billion in 2016, after reaching \$1.64 billion in 2015. We now see only modest sales growth for Viekira Pak following a FDA warning in October 2015 regarding liver failure or death with some patients taking Viekira. Also, Merck's Zepatier, a once-daily single tablet, was approved in January 2016 and was priced at \$54,600, much lower than Viekira Pak.
- We see 2016 EPS of \$5.03.

Investment Rationale/Risk

- We believe the shares are attractively valued trading at 10.9X our 2016 EPS estimate, well below peers. We believe ABBV's shares have weakened following the FDA warning in October, and we see more pressure after the approval of Merck's Zepatier in January 2016. However, ABBV outlined its long-term strategic and financial objectives and sees sales rising to \$37 billion in 2020 with double digit EPS growth on average through 2020. The company expects to launch more than 20 new products or indications through 2020. ABBV believes its pipeline has the potential to deliver about \$30 billion in nominal peak-year sales. Operating margin could reach over 50% in 2020 with an average of 100-200 basis point improvement per year. We believe these goals are impressive, but aggressive, particularly its new product launches. Humira's patent expires in Dec. 2016. In January 2016, the FDA accepted for review Amgen's application for a biosimilar of Humira.
- Risks to our recommendation and target price include pipeline failures.
- Our 12-month target price of \$84 applies an inline-to-peers 16.7X our 2016 EPS estimate.

Please read the Required Disclosures and Analyst Certification on the last page of this report.

Redistribution or reproduction is prohibited without written permission. This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. Investors should seek independent financial advice regarding the suitability and/or appropriateness of making an investment or implementing the investment strategies discussed in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such investments, if any, may fluctuate and that the value of such investments may rise or fall. Accordingly, investors may receive back less than they originally invested. Investors should seek advice concerning any impact this investment may have on their personal tax position from their own tax advisor. Please note the publication date of this document. It may contain specific information that is no longer current and should not be used to make an investment decision. Unless otherwise indicated, there is no intention to update this document.

AbbVie Inc

Business Summary January 29, 2016

CORPORATE OVERVIEW. AbbVie Inc. is a global research-based drug business that emerged as a separate company following its spin-off from Abbott Laboratories to Abbott shareholders on a share-for-share basis on January 1, 2013.

AbbVie's key product is Humira, an injectable biologic TNF (tumor necrosis factor) blocker treatment for rheumatoid arthritis (RA) and similar conditions, with sales of \$10.59 billion in 2013, up from \$9.3 billion in 2012 and \$7.9 billion in 2011. We estimate that Humira accounts for more than half of the global prescription drug market for rheumatoid arthritis. Besides moderate to severe RA in adults, Humira is also approved for many other uses, including juvenile idiopathic arthritis, psoriasis, ankylosing spondylitis, ulcerative colitis, Crohn's disease and axial spondyloarthritis.

Humira's U.S. composition of matter patent is expected to expire at the end of 2016, with its equivalent European Union patent set to expire in most EU countries in April 2018. Competitors in the rheumatoid arthritis market include Remicade (marketed by Johnson & Johnson), Simponi (Johnson & Johnson) and Enbrel (Pfizer).

Dyslipidemia products comprise treatments for high cholesterol and/or high triglycerides such as Tricor and Trilipix fibric acid derivatives fell 72.4% in 2013 to \$303 million from \$1.1 billion in 2012 as it went off-patent in late 2012, Niaspan extended release niacin fell 28.7% to \$650 million in 2013 from \$911 million. Metabolic/hormonal products include Synthroid treatment for hypothyroidism rose 12.9% to \$622 million from \$551 million, and AndroGel testosterone replacement fell 13.8% to \$1.035 billion from \$1.2 billion. Virology products comprise primarily Kaletra and Norvir HIV treatments fell 4.2% to \$962 million while Lupron for prostate cancer was flat at \$785 million. ABBV's key endocrinology drug, Synagis for respiratory syncytial virus is marketed outside of the U.S. was flat at \$827 million.

CORPORATE STRATEGY. AbbVie's strategic objectives include expanding Humira's sales through greater penetration of emerging markets, increased emphasis on earlier diagnosis of autoimmune patients, and new indications. ABBV also plans to launch five significant new products over the 2013-2016 time frame.

PIPELINE. AbbVie has an R&D pipeline of some 20 compounds or indications in Phase II or Phase III development across a fairly wide spectrum, including immunology, renal care, hepatitis C, women's health, oncology, multiple sclerosis, and Parkinson's and Alzheimer's diseases. In December 2014, the FDA approved Viekira Pak, to treat hepatitis C. Key planned launches include a levodopa-carbidopa intestinal gel (LCIG) in the U.S. for advanced Parkinson's disease; elotuzumab, a humanized monoclonal antibody for the treatment of multiple myeloma; daclizumab, a monoclonal antibody for the treatment of multiple sclerosis; ABT-199, a next-generation bcl-2 inhibitor in development for chronic lymphocytic leukemia; and new indications for Humira.

Key Phase III clinical programs include atrasentan for diabetic kidney disease and ABT-199 in chronic lymphocytic leukemia (CLL). Other important programs are planned Phase IIB starts for: elagolix in uterine fibroids; work on a partnered JAK1 inhibitor for rheumatoid arthritis (RA); BT-061 for RA; and ABT-719 for acute kidney injury associated with major cardiac and other surgeries. ABBV also intends to present clinical data on key development programs, including its rapidly advancing HCV program, oncology, renal disease, immunology and Alzheimer's disease.

MARKET PROFILE. The dollar value of the global drug market is projected to grow at a CAGR (compound annual growth rate) of 3%-6% over the 2012-2016 period, according to forecasts made by IMS Health. The key driver should be emerging markets, whose aggregate sales (17 countries) should advance at a CAGR of 12%-15% over the same period. Growth in developing markets is being spurred by rising standards of living and growing government spending on health care. However, IMS forecasts declining trends in Europe, with combined drug spending for five major European markets projected to decline at a CAGR of 1%-2% over 2012-2016. On the other hand, spending in the U.S. was forecast to grow at a CAGR of 1%-4% over the same period.

Corporate Information

Office
1 North Waukegan Road, North Chicago, IL 60064.

Telephone
847-932-7900.

Website
<http://www.abbvie.com>

Officers

Chrmn & CEO R.A. Gonzalez	EVP & CSO M. Severino
---	-------------------------------------

COO A. Saleki-Gerhardt	Secy & General Counsel L.J. Schumacher
----------------------------------	--

EVP & CFO W.J. Chase

Board Members

R. J. Alpern	R. S. Austin
W. H. Burnside	R. A. Gonzalez
E. M. Liddy	E. J. Rapp
R. S. Roberts	G. F. Tilton
F. H. Waddell	

Domicile
Delaware

Founded
2012

Employees
26,000

Stockholders
56,161

AbbVie Inc

Quantitative Evaluations						
S&P Capital IQ Fair Value Rank	5- <table border="1"> <tr> <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> </tr> </table> <small>LOWEST HIGHEST</small> Based on S&P Capital IQ's proprietary quantitative model, stocks are ranked from most overvalued (1) to most undervalued (5).	1	2	3	4	5
1	2	3	4	5		
Fair Value Calculation	\$108.00 Analysis of the stock's current worth, based on S&P Capital IQ's proprietary quantitative model suggests that ABBV is Undervalued by \$55.42 or 105.4%.					
Investability Quotient Percentile	<table border="1"> <tr> <td colspan="2">91</td> </tr> </table> <small>LOWEST = 1 HIGHEST = 100</small> ABBV scored higher than 91% of all companies for which an S&P Capital IQ Report is available.	91				
91						
Volatility	<table border="1"> <tr> <td>LOW</td> <td>AVERAGE</td> <td>HIGH</td> </tr> </table>	LOW	AVERAGE	HIGH		
LOW	AVERAGE	HIGH				
Technical Evaluation	BEARISH Since February, 2016, the technical indicators for ABBV have been BEARISH.					
Insider Activity	NA <table border="1"> <tr> <td>UNFAVORABLE</td> <td>NEUTRAL</td> <td>FAVORABLE</td> </tr> </table>	UNFAVORABLE	NEUTRAL	FAVORABLE		
UNFAVORABLE	NEUTRAL	FAVORABLE				

Expanded Ratio Analysis		2014	2013	2012	2011
Price/Sales		5.28	4.51	2.97	Nil
Price/EBITDA		15.71	11.80	7.05	Nil
Price/Pretax Income		44.47	15.89	9.55	Nil
P/E Ratio		59.39	20.52	10.36	Nil
Avg. Diluted Shares Outstg (M)		1,610.0	1,604.0	1,600.0	1,585.0

Figures based on calendar year-end price

Key Growth Rates and Averages		1 Year	3 Years	5 Years	9 Years
Past Growth Rate (%)					
Sales		6.23	4.01	6.76	NA
Net Income		-57.03	-18.58	-11.70	NA
Ratio Analysis (Annual Avg.)					
Net Margin (%)		8.89	19.85	20.93	NA
% LT Debt to Capitalization		64.70	73.98	77.19	NA
Return on Equity (%)		56.62	76.25	NA	NA

For further clarification on the terms used in this report, please visit www.spcapitaliq.com/stockreportguide

Company Financials		Fiscal Year Ended Dec. 31									
	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	
Per Share Data (\$)											
Tangible Book Value	NA	NM	NM	NM	NM	NA	NA	NA	NA	NA	
Cash Flow	NA	1.59	3.13	4.07	NA	NA	NA	NA	NA	NA	
Earnings	3.13	1.10	2.56	3.35	2.03	NA	NA	NA	NA	NA	
S&P Capital IQ Core Earnings	NA	1.09	2.59	3.37	2.80	2.64	NA	NA	NA	NA	
Dividends	2.02	1.66	1.60	Nil	NA	NA	NA	NA	NA	NA	
Payout Ratio	65%	151%	63%	Nil	NA	NA	NA	NA	NA	NA	
Prices:High	71.60	70.76	54.78	37.07	NA	NA	NA	NA	NA	NA	
Prices:Low	45.45	45.50	33.33	32.51	NA	NA	NA	NA	NA	NA	
P/E Ratio:High	23	64	21	11	NA	NA	NA	NA	NA	NA	
P/E Ratio:Low	15	41	13	10	NA	NA	NA	NA	NA	NA	
Income Statement Analysis (Million \$)											
Revenue	NA	19,960	18,790	18,380	17,639	15,638	14,214	NA	NA	NA	
Operating Income	NA	6,708	7,181	7,758	NA	6,361	5,826	NA	NA	NA	
Depreciation	NA	786	897	1,150	NA	1,184	697	NA	NA	NA	
Interest Expense	NA	429	299	104	292	NA	NA	NA	NA	NA	
Pretax Income	NA	2,369	5,332	5,725	3,367	4,836	5,950	NA	NA	NA	
Effective Tax Rate	NA	25.1%	22.6%	7.86%	3.70%	13.6%	22.1%	NA	NA	NA	
Net Income	NA	1,774	4,128	5,275	3,243	4,178	4,637	NA	NA	NA	
S&P Capital IQ Core Earnings	NA	1,752	4,146	5,389	4,432	4,182	NA	NA	NA	NA	
Balance Sheet & Other Financial Data (Million \$)											
Cash	NA	8,374	9,895	7,976	7,200	NA	NA	NA	NA	NA	
Current Assets	NA	16,088	17,848	15,354	13,546	NA	NA	NA	NA	NA	
Total Assets	NA	27,547	29,198	27,008	25,948	NA	NA	NA	NA	NA	
Current Liabilities	NA	11,400	6,879	6,776	6,368	NA	NA	NA	NA	NA	
Long Term Debt	NA	10,565	14,292	14,630	14,700	NA	NA	NA	NA	NA	
Common Equity	NA	1,742	4,492	3,363	2,230	NA	NA	NA	NA	NA	
Total Capital	NA	16,328	18,802	18,015	16,930	NA	NA	NA	NA	NA	
Capital Expenditures	NA	612	491	333	NA	NA	NA	NA	NA	NA	
Cash Flow	NA	2,560	5,025	6,425	NA	NA	NA	NA	NA	NA	
Current Ratio	NA	1.4	2.6	2.3	2.1	NA	NA	NA	NA	NA	
% Long Term Debt of Capitalization	NA	64.7	76.0	81.2	86.8	NA	NA	NA	NA	NA	
% Net Income of Revenue	NA	8.9	22.0	28.7	NA	NA	NA	NA	NA	NA	
% Return on Assets	NA	6.3	14.7	22.6	NA	NA	NA	NA	NA	NA	
% Return on Equity	NA	56.6	104.4	67.7	NA	NA	NA	NA	NA	NA	

Data as originally reported in Company reports.; bef. results of disc opers/spec. items. Per share data adj. for stk. divs.; EPS diluted. E-Estimated. NA-Not Available. NM-Not Meaningful. NR-Not Ranked. UR-Under Review.

AbbVie Inc

Sub-Industry Outlook

Our positive fundamental outlook for the biotechnology sub-industry for the next 12 months reflects favorable prospects for new and novel therapies to reach commercialization. We are encouraged by what we view as a strong period for the reporting of late-stage clinical results, and a more accommodating U.S. FDA for approvals. In 2014, the FDA approved 41 new therapies, up from 27 in 2013, the most since a record 53 were approved in 1996. We think many of these newly approved drugs have significant commercial prospects and represent major advances in therapeutic areas such as hepatitis C, multiple sclerosis and cancer. We expect wider adoption of biomarker research and genetic-targeted clinical studies to help bolster long-term R&D pipeline productivity. In late 2012, the FDA introduced "breakthrough therapy" designations, intended to speed development of promising programs.

We expect a favorable mergers and acquisitions (M&A) climate, as large pharmaceutical firms move to offset lost revenues from expiring drug patents and large biotechs bolster their drug pipelines amid maturing products. We note an uptick in M&A speculation and announced deals recently. We also see large cap biotechs generating cash flows supporting larger scale acquisitions of their own. In 2011, industry bellwether Amgen became the first biotech company to initiate a regular dividend. Gilead Sciences will begin dividend payments in 2015.

The 2010 health care reform law established the FDA's authorization to govern "biosimilar" drug approvals and set a 12-year exclusivity to branded drugmakers. We see biosimilars advancing at a slower rate than initially anticipated. In March 2015, the FDA approved Novartis' biosimilar of Amgen's Neupogen. Also in August, Celltrion filed for

approval of its biosimilar of Johnson and Johnson's Remicade. Once marketed, we expect biosimilars to sell at more modest price discounts than generics in the pharmaceutical industry due to higher clinical, manufacturing and marketing costs, and we expect branded drugs to retain significant market share due to a lack of interchangeability among these options.


We recommend that investors concentrate core holdings in established, profitable companies, as smaller biotechs tend to be more volatile. We would seek companies with at least two years of operating capital and multiple pipeline drivers, as those with smaller pipelines typically suffer significant share price declines on an unfavorable outcome. In 2014, the S&P Biotech Index rose 32.3%, vs. a 10.9% gain for the S&P 1500 Index. Year-to-date through Aug. 14, the S&P Biotech Index rose 12.9%, vs. a 1.7% rise for the S&P 1500 Index.

--Jeffrey Loo, CFA

Industry Performance

GICS Sector: Health Care
Sub-Industry: Biotechnology

Based on S&P 1500 Indexes
Five-Year market price performance through Feb 13, 2016



NOTE: All Sector & Sub-Industry information is based on the Global Industry Classification Standard (GICS)

Past performance is not an indication of future performance and should not be relied upon as such.

Sub-Industry : Biotechnology Peer Group*: Based on market capitalizations within GICS Sub-Industry

Peer Group	Stock Symbol	Stk.Mkt. Cap. (Mil. \$)	Recent Stock Price(\$)	52 Week High/Low(\$)	Beta	Yield (%)	P/E Ratio	Fair Value Calc.(\$)	Quality Ranking	S&P IQ %ile	Return on Revenue (%)	LTD to Cap (%)
AbbVie Inc	ABBV	85,955	52.58	71.60/45.45	1.66	4.3	17	108.00	NR	91	8.9	64.7
ACADIA Pharmaceuticals	ACAD	1,842	18.26	51.99/16.64	NM	Nil	NM	NA	C	72	NM	NA
Alnylam Pharmaceuticals	ALNY	3,806	59.55	140.00/51.51	NA	Nil	NM	NA	C	74	NM	NA
Anacor Pharmaceuticals	ANAC	3,131	70.95	156.93/40.46	1.40	Nil	NM	NA	NR	49	NM	43.2
Baxalta Inc	BXLT	26,237	38.67	42.38/29.83	NA	0.7	16	NA	NR	83	19.9	NA
China Biologic Products	CBPO	2,833	106.77	144.29/69.34	1.56	Nil	34	NA	NR	67	29.2	12.7
Grifols SA ADR	GRFS	10,026	14.67	18.04/14.07	0.93	1.8	16	NA	NR	12	13.7	59.0
Intercept Pharmaceuticals	ICPT	2,925	120.22	314.88/89.76	NM	Nil	NM	NA	NR	72	NM	NA
Intrexon Corp	XON	3,257	29.67	69.45/18.52	NA	Nil	NM	NA	NR	43	NM	2.1
Kite Pharma	KITE	1,875	42.88	89.84/38.41	NA	Nil	NM	NA	NR	73	NA	NA
Medivation Inc	MDVN	4,974	30.44	70.79/26.41	1.02	Nil	19	56.40	B-	80	38.9	33.1
Ophthotech Corp	OPHT	1,660	47.47	80.00/35.72	NA	Nil	NM	NA	NR	9	NM	45.9
Opko Health	OPK	3,657	7.89	19.20/7.12	1.03	Nil	NM	NA	C	55	NM	13.7
Seattle Genetics	SGEN	3,590	28.64	52.33/26.02	1.38	Nil	NM	NA	C	42	NM	NA
Ultragenyx Pharmaceutical	RARE	2,127	54.77	137.05/49.00	NA	Nil	NM	NA	NR	71	NA	NA

NA-Not Available NM-Not Meaningful NR-Not Rated. *For Peer Groups with more than 15 companies or stocks, selection of issues is based on market capitalization.

AbbVie Inc**S&P Capital IQ Analyst Research Notes and other Company News****January 29, 2016**

10:17 am ET ... S&P CAPITAL IQ KEEPS BUY OPINION ON SHARES OF ABBVIE INC. (ABBV 54.61****): We keep our 12-month target at \$84 on in-line to peers 16.7X PE on revised '16 EPS estimate of \$5.03, up from \$4.98, but below peers 0.9X PEG. Q4 EPS of \$1.13 vs. \$0.89 is \$0.01 ahead of our estimate. We set '17 EPS at \$5.93. Sales rose 18.4% on strong Humira, Imbruvica and Viekara sales. Imbruvica sales were \$343M and we see ABBV's share of Imbruvica sales reaching \$1.3B in 2016. Viekara sales were \$554M, but Merck (MRK 51 ****) received approval for its hepatitis C drug, Zepatier, and priced it at \$54,600, much lower than Viekara, which we believe may pressure sales in 2016. /Jeffrey Loo, CFA

January 29, 2016

09:30 am ET ... S&P CAPITAL IQ KEEP HOLD OPINION ON SHARES OF MERCK (MRK 49.20****): MRK received FDA approval for its combination (grazoprevir and elbasvir) hepatitis C drug, Zepatier, a once-daily tablet. MRK priced Zepatier at \$54,600 for a 12-week regimen, well below Gilead Sciences' (GILD 88 *****) Harvoni, priced at \$94,500 and AbbVie's (ABBV 56 ****) priced at \$83,000. We believe Zepatier's price may improve patient access to treatment, particularly in the public segment. Zepatier has a cure rate of 94%, but we see GILD maintaining a dominant market share as Zepatier's label requires liver monitoring and recommends screening for mutations in the virus. /Jeffrey Loo, CFA

October 30, 2015

10:29 am ET ... S&P CAPITAL IQ KEEPS BUY OPINION ON SHARES OF ABBVIE (ABBV 59.70****): We raise our 12-month target \$6 to \$84 on in-line to peers 18X our forward 12-months EPS estimate of \$4.70. Q3 EPS of \$1.13 vs. \$0.89 is \$0.05 ahead of our estimate. We raise our 2015 EPS estimate \$0.07 to \$4.27. Sales grew 18% with strong Humira and imbruvica sales, but viekira sales were below our forecast. We see modest sales of viekira due to recent FDA warning and more competition in 2016. ABBV provided long term objectives with sales reaching \$37B by 2020, with Humira and Imbruvica sales of \$18B and \$5B. It plans to launch 20 new products or indications by 2020. /Jeffrey Loo, CFA

July 27, 2015

11:30 am ET ... S&P CAPITAL IQ ADDS ABBVIE TO ITS TOTAL RETURN PORTFOLIO (ABBV 69.11****): Since being spun-off from Abbott Labs in '13, ABBV has experienced strong growth, aided by acquisitions and an expanded drug portfolio. Excluding forex, last week ABBV reported Q2 revenues rose 19%, driven by 16% growth in Humira. ABBV sees international growth improving in the 2H of '15. ABBV, which raised its dividend in Feb '15, now sports a 3.0% dividend yield. ABBV replaces Lexmark Intl (LXK 33 ****) in our Total Return portfolio. /Todd Rosenbluth

July 24, 2015

10:30 am ET ... S&P CAPITAL IQ KEEPS BUY RECOMMENDATION ON SHARES OF ABBVIE (ABBV 68.55****): We cut our 12-month target \$2 to \$76, applying a peer based P/E of 18X to our 2015 EPS estimate of \$4.20, down from \$4.30. Q2 adjusted EPS of \$1.08 vs. \$0.82 is \$0.03 above our estimate. Excluding forex, revenues rose 19%, below Cap IQ consensus, on 16% growth in Humira. ABBV keeps 8%-9% international growth target for Humira in '15 despite only 3.6% growth in Q2 due to a shift in shipment timing. Viekira sales of \$385 million missed consensus and ABBV target on weaker than expected U.S. performance due to weak patient volumes and Veterans Administration funding difficulties. /Jeffrey Loo, CFA, /J. Agnese

April 23, 2015

12:11 pm ET ... S&P CAPITAL IQ MAINTAINS BUY OPINION ON SHARES OF ABBVIE (ABBV 63.575****): We keep our 12-month target at \$78 on in-line to peers 18X our '15 EPS est. Q1 EPS of \$0.94 vs. \$0.71 is \$0.07 ahead of our estimate. Sales, with adverse 7.3% forex, rose 10.5% on robust Humira sales, up 18%. But Viekira had a modest launch with sales of \$231M. ABBV stated prescription tracking data is understating prescriptions and said int'l launch is progressing well and talks with gov't payers are advancing rapidly, which should lead to faster sales. ABBV still sees Viekira at \$3B annualized run-rate by end of '15 as many of its US contracts have start dates in April and May. /Jeffrey Loo, CFA

March 5, 2015

11:23 am ET ... S&P CAPITAL IQ REITERATES BUY OPINION ON SHARES OF ABBVIE (ABBV 58.66****): ABBV will acquire Pharmacyclics (PCYC 255, NR) for \$261.25/sh or \$21B. PCYC's Imbruvica is approved for 3 blood cancers and had

sales of \$548M in '14. We see sales of \$1B in 2015 and up to \$4B in 2020, but we note Imbruvica is co-promoted with Johnson & Johnson (JNJ 103 ****). ABBV sees peak sales for Imbruvica at over \$7B, but Imbruvica needs approval for more indications to reach that level. This deal gives ABBV a presence in blood cancers and provides an experienced sales force as ABBV has its own blood cancer drug, ABT 199 that we think it can file an NDA later this year. /Jeffrey Loo, CFA

January 30, 2015

02:30 pm ET ... CORRECTION S&P CAPITAL IQ RAISES OPINION ON SHARES OF ABBVIE TO BUY FROM HOLD (ABBV 60.88****): We keep our 12-month target at \$78 on an in-line with peers 17.9X our '15 EPS estimate of \$4.36. We think the shares, now trading at 13.8X our '15 estimate due to recent decline, are attractively valued. Q4 EPS of \$0.89, vs. \$0.82, is \$0.04 ahead of our estimate. Sales grew 5.1% and gross margin expanded 410 basis points. ABBV forecasts Viekira sales will achieve an annualized run rate of more than \$3B by the end of 2015 (prior version said ABBV forecasts \$3B in 2015) and has access to 40% of insured patients. We think Gilead will maintain dominant market share in hepatitis C. /Jeffrey Loo, CFA


January 30, 2015

11:22 am ET ... S&P CAPITAL IQ RAISES OPINION ON SHARES OF ABBVIE TO BUY FROM HOLD (ABBV 60.535****): We keep our 12-month target at \$78 on an in-line with peers 17.9X our '15 EPS estimate of \$4.36. We think the shares, now trading at 13.8X our '15 estimate due to recent decline, are attractively valued. Q4 EPS of \$0.89, vs. \$0.82, is \$0.04 ahead of our estimate. Sales grew 5.1% and gross margin expanded 410 basis points. ABBV forecasts \$3B in '15 sales for recently launched Viekira for Hepatitis C and estimates it has access to 40% of insured patients. But we think \$3B in sales is aggressive and we see about \$2.4B-\$2.5B as we expect Gilead to maintain dominant market share. /Jeffrey Loo, CFA

January 9, 2015

11:34 am ET ... S&P CAPITAL IQ MAINTAINS HOLD OPINION ON SHARES OF ABBVIE (ABBV 65.47****): We keep our target price at \$78 on an in-line to peers 17.9X on our revised 2015 EPS estimate of \$4.36, up from \$4.30. ABBV provides 2015 EPS guidance of \$4.25-\$4.45 with results expected to be driven by strong growth from Humira as well as from the launch of recently approved hepatitis C drug Viekira, partially offset by a decline in several products due to generic competition, including AndroGel. ABBV also reported positive Phase III data yesterday on Elagolix to treat endometriosis. ABBV will provide detailed 2015 sales guidance on Jan. 30. We forecast 17.9% growth to \$23.1B. /Jeffrey Loo, CFA

AbbVie Inc



Wall Street Consensus Opinion

BUY/HOLD


Companies Offering Coverage

- Argus Research Company
- Atlantic Equities LLP
- BMO Capital Markets Equity Research
- Barclays
- BofA Merrill Lynch
- Citigroup Inc
- Cowen and Company, LLC
- Credit Suisse
- Erste Group Bank AG
- Evercore ISI
- Goldman Sachs
- Guggenheim Securities, LLC
- JMP Securities
- JP Morgan
- Jefferies LLC
- Morgan Stanley
- Morningstar Inc.
- Piper Jaffray Companies
- SunTrust Robinson Humphrey, Inc.
- UBS Investment Bank
- William Blair & Company L.L.C.

Of the total 21 companies following ABBV, 21 analysts currently publish recommendations.

	No. of Recommendations	% of Total	1 Mo. Prior	3 Mos. Prior
Buy	7	33	0	7
Buy/Hold	7	33	0	6
Hold	6	29	0	5
Weak Hold	0	0	0	0
Sell	0	0	0	0
No Opinion	1	5	0	1
Total	21	100	0	19

Wall Street Consensus Estimates



Fiscal Years	Avg Est.	High Est.	Low Est.	# of Est.	Est. P/E
2017	5.97	6.32	5.53	17	8.8
2016	5.04	5.18	4.94	19	10.4
2017 vs. 2016	▲ 18%	▲ 22%	▲ 12%	▼ -11%	▼ -15%
Q1'17	1.34	1.50	1.17	2	39.2
Q1'16	1.13	1.18	1.03	14	46.5
Q1'17 vs. Q1'16	▲ 19%	▲ 27%	▲ 14%	▼ -86%	▼ -16%

Wall Street Consensus vs. Performance

For fiscal year 2016, analysts estimate that ABBV will earn US\$ 5.04. For fiscal year 2017, analysts estimate that ABBV's earnings per share will grow by 18% to US\$ 5.97.

A company's earnings outlook plays a major part in any investment decision. S&P Capital IQ organizes the earnings estimates of over 2,300 Wall Street analysts, and provides their consensus of earnings over the next two years, as well as how those earnings estimates have changed over time. Note that the information provided in relation to consensus estimates is not intended to predict actual results and should not be taken as a reliable indicator of future performance.

Glossary

S&P Capital IQ STARS

Since January 1, 1987, S&P Capital IQ Equity Research has ranked a universe of U.S. common stocks, ADRs (American Depositary Receipts), and ADSs (American Depositary Shares) based on a given equity's potential for future performance. Similarly, S&P Capital IQ Equity Research has ranked Asian and European equities since June 30, 2002. Under proprietary STARS (STock Appreciation Ranking System), S&P Capital IQ equity analysts rank equities according to their individual forecast of an equity's future total return potential versus the expected total return of a relevant benchmark (e.g., a regional index (S&P Asia 50 Index, S&P Europe 350® Index or S&P 500® Index)), based on a 12-month time horizon. STARS was designed to meet the needs of investors looking to put their investment decisions in perspective. Data used to assist in determining the STARS ranking may be the result of the analyst's own models as well as internal proprietary models resulting from dynamic data inputs.

S&P Capital IQ Quality Ranking

(also known as **S&P Capital IQ Earnings & Dividend Rankings**) - Growth and stability of earnings and dividends are deemed key elements in establishing S&P Capital IQ's earnings and dividend rankings for common stocks, which are designed to encapsulate the nature of this record in a single symbol. It should be noted, however, that the process also takes into consideration certain adjustments and modifications deemed desirable in establishing such rankings. The final score for each stock is measured against a scoring matrix determined by analysis of the scores of a large and representative sample of stocks. The range of scores in the array of this sample has been aligned with the following ladder of rankings:

A+ Highest	B Below Average
A High	B- Lower
A- Above Average	C Lowest
B+ Average	D In Reorganization
NR Not Ranked	

S&P Capital IQ EPS Estimates

S&P Capital IQ earnings per share (EPS) estimates reflect analyst projections of future EPS from continuing operations, and generally exclude various items that are viewed as special, non-recurring, or extraordinary. Also, S&P Capital IQ EPS estimates reflect either forecasts of S&P Capital IQ equity analysts; or, the consensus (average) EPS estimate, which are independently compiled by Capital IQ, a data provider to S&P Capital IQ Equity Research. Among the items typically excluded from EPS estimates are asset sale gains; impairment, restructuring or merger-related charges; legal and insurance settlements; in process research and development expenses; gains or losses on the extinguishment of debt; the cumulative effect of accounting changes; and earnings related to operations that have been classified by the company as discontinued. The inclusion of some items, such as stock option expense and recurring types of other charges, may vary, and depend on such factors as industry practice, analyst judgment, and the extent to which some types of data is disclosed by companies.

S&P Capital IQ Core Earnings

S&P Capital IQ Core Earnings is a uniform methodology for adjusting operating earnings by focusing on a company's after-tax earnings generated from its principal businesses. Included in the S&P Capital IQ definition are employee stock option grant expenses, pension costs, restructuring charges from ongoing operations, write-downs of depreciable or amortizable operating assets, purchased research and development, M&A related expenses and unrealized gains/losses from hedging activities. Excluded from the definition are pension gains, impairment of goodwill charges, gains or losses from asset sales, reversal of prior-year charges and provision from litigation or insurance settlements.

S&P Capital IQ 12-Month Target Price

The S&P Capital IQ equity analyst's projection of the market price a given security will command 12 months hence, based on a combination of intrinsic, relative, and private market valuation metrics, including S&P Capital IQ Fair Value.

S&P Capital IQ Equity Research

S&P Capital IQ Equity Research U.S. includes Standard & Poor's Investment Advisory Services LLC; Standard & Poor's Equity Research Services Europe includes McGraw-Hill Financial Research Europe Limited trading as S&P Capital IQ; Standard & Poor's Equity Research Services Asia includes: McGraw-Hill Financial Singapore Pte. Limited, Standard & Poor's Investment Advisory Services (HK) Limited, Standard & Poor's Malaysia Sdn Bhd, and Standard & Poor's Information Services (Australia) Pty Ltd.

Abbreviations Used in S&P Capital IQ Equity Research Reports

CAGR - Compound Annual Growth Rate
CAPEX - Capital Expenditures
CY - Calendar Year
DCF - Discounted Cash Flow
DDM - Dividend Discount Model

EBIT - Earnings Before Interest and Taxes
EBITDA - Earnings Before Interest, Taxes, Depreciation and Amortization
EPS - Earnings Per Share
EV - Enterprise Value
FCF - Free Cash Flow
FFO - Funds From Operations
FY - Fiscal Year
P/E - Price/Earnings
P/NAV - Price to Net Asset Value
PEG Ratio - P/E-to-Growth Ratio
PV - Present Value
R&D - Research & Development
ROCE - Return on Capital Employed
ROE - Return on Equity
ROI - Return on Investment
ROIC - Return on Invested Capital
ROA - Return on Assets
SG&A - Selling, General & Administrative Expenses
SOTP - Sum-of-The-Parts
WACC - Weighted Average Cost of Capital

Dividends on American Depositary Receipts (ADRs) and American Depositary Shares (ADSs) are net of taxes (paid in the country of origin).

S&P Capital IQ Qualitative Risk Assessment

Reflects an S&P Capital IQ equity analyst's view of a given company's operational risk, or the risk of a firm's ability to continue as an ongoing concern. The S&P Capital IQ Qualitative Risk Assessment is a relative ranking to the S&P U.S. STARS universe, and should be reflective of risk factors related to a company's operations, as opposed to risk and volatility measures associated with share prices. For an ETF this reflects on a capitalization-weighted basis, the average qualitative risk assessment assigned to holdings of the fund.

STARS Ranking system and definition:

★★★★★ 5-STAR (Strong Buy):

Total return is expected to outperform the total return of a relevant benchmark, by a wide margin over the coming 12 months, with shares rising in price on an absolute basis.

★★★★☆ 4-STAR (Buy):

Total return is expected to outperform the total return of a relevant benchmark over the coming 12 months, with shares rising in price on an absolute basis.

★★★☆☆ 3-STAR (Hold):

Total return is expected to closely approximate the total return of a relevant benchmark over the coming 12 months, with shares generally rising in price on an absolute basis.

★★☆☆☆ 2-STAR (Sell):

Total return is expected to underperform the total return of a relevant benchmark over the coming 12 months, and the share price not anticipated to show a gain.

★☆☆☆☆ 1-STAR (Strong Sell):

Total return is expected to underperform the total return of a relevant benchmark by a wide margin over the coming 12 months, with shares falling in price on an absolute basis.

Relevant benchmarks:

In North America, the relevant benchmark is the S&P 500 Index, in Europe and in Asia, the relevant benchmarks are the S&P Europe 350 Index and the S&P Asia 50 Index, respectively.

Disclosures

S&P Capital IQ ranks stocks in accordance with the following ranking methodologies:

STARS Stock Reports:

S&P Capital IQ's qualitative STARS recommendations are determined and assigned by S&P Capital IQ equity analysts. For reports containing STARS recommendations refer to the Glossary section of the report for detailed methodology and the definition of STARS rankings.

Quantitative Stock Reports:

S&P Capital IQ's quantitative recommendations quantitative recommendations are determined by ranking a universe of common stocks based on 5 measures or model categories: Valuation, Quality, Growth, Street Sentiment, and Price Momentum. In the U.S., a sixth sub-category for Financial Health will also be displayed. Percentile scores are used to compare each company to all other companies in the same universe for each model category. The five (six) model category scores are then weighted and rolled up into a single percentile ranking for that company. For reports containing quantitative recommendations refer to the Glossary section of the report for detailed methodology and the definition of Quantitative rankings.

STARS Stock Reports and Quantitative Stock Reports:

The methodologies used in STARS Stock Reports and Quantitative Stock Reports (collectively, the "S&P Capital IQ's Research Reports" or "Research Reports") reflect different criteria, assumptions and analytical methods and may have differing recommendations. S&P Capital IQ believes that the methodologies and data used to generate the different types of Research Reports are reasonable and appropriate. Generally, S&P Capital IQ does not generate reports with different ranking methodologies for the same issuer. However, in the event that different methodologies or data are used on the analysis of an issuer, the methodologies may lead to different views or recommendations on the issuer, which may at times result in contradicting assessments of an issuer. S&P Capital IQ reserves the right to alter, replace or vary models, methodologies or assumptions from time to time and without notice to clients.

STARS Stock Reports:

S&P Capital IQ Global STARS Distribution as of December 31, 2015

Ranking	North America	Europe	Asia	Global
Buy	31.2%	51.5%	35.5%	35.1%
Hold	46.8%	39.4%	35.5%	43.9%
Sell	22.0%	9.1%	29.0%	21.0%
Total	100%	100%	100%	100%

Quantitative Stock Reports:

The rankings for Quantitative reports have a fixed distribution based on relative weightings as described in the Glossary section of the report.

Analyst Certification

STARS Stock Reports are prepared by the equity research analysts of Standard & Poor's Investment Advisory Services LLC ("SPIAS"), McGraw-Hill Financial Research Europe Limited ("MHFRE"), and Standard & Poor's Malaysia Sdn Bhd ("S&P Malaysia"), each a division of S&P Capital IQ. All of the views expressed in STARS Stock Reports accurately reflect the research analyst's personal views regarding any and all of the subject securities or issuers. Analysts generally update stock reports at least four times each year. No part of analyst compensation and SPIAS', MHFRE's or S&P Malaysia's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in a STARS Stock Report.

About S&P Capital IQ's Distributors:

S&P Capital IQ's Research Reports have been prepared by Global Markets Intelligence ("GMI"), a business unit of S&P Capital IQ. In the United States, Research Reports are prepared and issued by SPIAS. In the European Economic Area ("EEA") States, Research Reports are distributed by MHFRE, which is authorized and regulated by the Financial Conduct Authority in the United Kingdom. Under and subject to the Markets in Financial Instruments Directive ("MiFID"), MHFRE is entitled to exercise a passport right to provide cross border investment advice into EEA States. MHFRE exercises its MiFID right to passport investment advice including the Research Reports into EEA States. In Hong Kong, Research Reports are issued by Standard & Poor's Investment Advisory Services (HK) Limited ("SPIAS HK"), which is regulated by the Hong Kong Securities Futures Commission; in Singapore, by McGraw-Hill Financial Singapore Pte. Limited ("MHFSPL"), which is regulated by the Monetary Authority of Singapore; Research Reports are distributed in Malaysia, by S&P Malaysia, which is regulated by the Securities Commission of Malaysia; in Australia, by Standard & Poor's Information Services (Australia) Pty Ltd ("SPIS"),

which is regulated by the Australian Securities & Investments Commission; and in Japan, by McGraw-Hill Financial Japan KK ("MHF Japan"), which is registered by Kanto Financial Bureau. SPIAS, MHFRE, SPIAS HK, MHFSPL, S&P Malaysia, SPIS and MHF Japan, each a wholly owned subsidiary of McGraw Hill Financial, Inc. operate under the GMI brand.

S&P Capital IQ and its affiliates provide a wide range of services to, or relating to, many organizations, including issuers of securities, investment advisers, broker-dealers, investment banks, other financial institutions and financial intermediaries, and accordingly may receive fees or other economic benefits from those organizations, including organizations whose securities or services they may recommend, rate, include in model portfolios, evaluate or otherwise address.

For details on the S&P Capital IQ research objectivity and conflict-of-interest policies, please visit: <https://www.spcapitaliq.com/disclaimers/s-p-capital-iq-research-reports>

For a list of companies mentioned in a Research Report for which McGraw Hill Financial, Inc. and/or one of its affiliates own 1% or more of common equity securities and for a list of companies mentioned in a Research Report that own more than 5% of the common equity securities of McGraw Hill Financial, Inc. and/or one of its affiliates, please visit: www.SPcapitaliq.com/issuer-stock-ownership

For a list of companies mentioned in a Research Report with whom S&P Capital IQ and/or one of its affiliates has had business relationships within the past year, please go to: www.spcapitaliq.com/relationships

S&P Capital IQ and/or one of its affiliates has performed services for and received compensation from this company during the past twelve months.

General Disclosure

Notice to all jurisdictions:

Where S&P Capital IQ's Research Reports are made available in a language other than English and in the case of inconsistencies between the English and translated versions of a Research Report, **the English version will control and supersede any ambiguities associated with any part or section of a Research Report that has been issued in a foreign language.** Neither S&P Capital IQ nor its affiliates guarantee the accuracy of the translation.

Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. This document may contain forward looking statements or forecasts, such statement or forecasts are not a reliable indicator of future performance.

Past performance is not necessarily indicative of future results.

No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of Standard & Poor's Financial Services LLC or its affiliates (collectively, S&P). The Content shall not be used for any unlawful or unauthorized purposes. S&P and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

While S&P Capital IQ has obtained information from sources it believes to be reliable, S&P Capital IQ does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P keeps certain activities of its business units separate from each other in order to

preserve the independence and objectivity of their respective activities. As a result, certain business units of S&P may have information that is not available to other S&P business units. S&P has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

Research Reports are not intended to be investment advice and do not constitute any form of invitation or inducement by S&P Capital IQ to engage in investment activity. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor's particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment, lose a portion of, or all of the principal amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's chosen currency, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in Research Reports does not constitute advice on the tax consequences of making any particular investment decision. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

Additional information on a subject company may be available upon request.

Notice to all Non U.S. Residents:

S&P Capital IQ's Research Reports may be distributed in certain localities, countries and/or jurisdictions ("Territories") by independent third parties or independent intermediaries and/or distributors (the "Intermediaries" or "Distributors"). Intermediaries are not acting as agents or representatives of S&P Capital IQ. In Territories where an Intermediary distributes S&P Capital IQ's Research Reports, the Intermediary, and not S&P Capital IQ, is solely responsible for complying with all applicable regulations, laws, rules, circulars, codes and guidelines established by local and/or regional regulatory authorities, including laws in connection with the distribution of third-party Research Reports, licensing requirements, supervisory and record keeping obligations that the Intermediary may have under the applicable laws and regulations of the territories where it distributes the Research Reports.

Each Research Report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject S&P Capital IQ or its affiliates to any registration or licensing requirements in such jurisdiction.

Each Research Report is not directed to, or intended for distribution to or use by, any person or entity who is not in a class qualified to receive Research Reports (e.g., a qualified person and/or investor), as defined by the local laws or regulations in the country or jurisdiction where the person is domiciled, a citizen or resident of, or the entity is legally registered or domiciled.

S&P Capital IQ's Research Reports are not intended for distribution in or directed to entities, residents or investors in: Burma, Cuba, Crimea, Czech Republic, Iran, Kuwait, Lebanon, North Korea, Portugal, Romania, Sudan, Slovakia, Syria, Thailand and Turkey.

For residents of Australia: Research Reports are distributed in Australia by SPIS. Any express or implied opinion contained in a Research Report is limited to "General Advice" and based solely on consideration of the investment merits of the financial product(s) alone. The information in a Research Report has not been prepared for use by retail investors and has been prepared without taking account of any particular investor's financial or investment objectives, financial situation or needs. Before acting on any advice, any investor using the advice should consider its appropriateness having regard to their own or their clients' objectives, financial situation and needs. Investors should obtain a Product Disclosure Statement relating to the product and consider the statement before making any decision or recommendation about whether to acquire the product. Each opinion must be weighed solely as one factor in any investment decision made by or on behalf of any adviser and any such adviser must accordingly make their own assessment taking into account an individual's particular circumstances.

SPIS holds an Australian Financial Services License Number 258896. Please refer to the SPIS Financial Services Guide for more information at: www.spcapitaliq.com/financialservicesguide

More information about the written criteria and methodologies for the generation of Research Reports and historical information for Research Reports for the past 12 months are available by contacting S&P Capital IQ Client Services Department at 61-1300-792-553 or via e-mail at clientsupport@standardandpoors.com or clientsupport@sandp.com.

For residents of Bahamas: The Intermediary, and not S&P Capital IQ, is solely responsible for complying with licensing requirements under the Securities Industry Act of 1999 and the Securities Industry Regulations of 2000 of The Bahamas, when distributing Research Reports to members of the public in The Bahamas. The Intermediary is also solely responsible for providing any required disclosures under applicable securities laws and regulations to its Bahamian clients, including but not limited to disclosing whether the Intermediary: (i) has a reasonable basis for specific investment recommendations, and the recommended security's price or price range at the time of the recommendation to the client; (ii) makes a market in the recommended security; (iii) its directors, officers or principal shareholders have a current or contingent financial interest in the recommended security, unless the interest is nominal; (iv) participated in a public offering of the recommended security in the last two (2) years; and (v) has disclosed any conflict of interest between it and the issuer of the recommended security.

For residents of Bermuda: The Bermuda Monetary Authority or the Registrar of Companies in Bermuda has not approved the Research Reports and any representation, explicit or implicit, is prohibited.

For residents of Brazil: Research reports are distributed by S&P Capital IQ and in compliance with Instruction 483 enacted by Comissão de Valores Mobiliários (the Brazilian Securities Commission) dated as of July 6, 2010, the analyst (where applicable) who prepares a Research Report or a report extract affirms: (i) that all the views expressed herein and/or in a Research Report accurately reflect his or her personal views about the securities and issuers; (ii) that all recommendations issued by him or her were independently produced, including from the opinion of the entity in which he or she is an employee. S&P Capital IQ is of the opinion its Research Reports have been prepared in accordance with section 17, II of Instruction 483. The Distributor of the Research Report is responsible for disclosing any circumstances that may impact the independence of S&P Capital IQ's Research Report, in accordance with section 17, II of Instruction 483.

For residents of British Virgin Islands: All products and services offered by S&P Capital IQ and its affiliates are provided or performed, outside of the British Virgin Islands. The intended recipients of the Research Reports are (i) persons who are not members of the public for the purposes of the Securities and Investment Business Act, 2010 ("SIBA"); (ii) persons who are professional services providers to the British Virgin Islands business companies for the purposes of SIBA; and (iii) any other person who is given the Research Reports by a person licensed as an investment advisor in the British Virgin Islands. If you are in any doubt as to whether you are the intended recipient of this document, please consult your licensed investment advisor.

For residents of Canada: Canadian investors should be aware that any specific securities discussed in a Research Report can only be purchased in Canada through a Canadian registered dealer and, if such securities are not available in the secondary market, they can only be purchased by eligible private placement purchasers on a basis that is exempt from the prospectus requirements of Canadian securities law and will be subject to resale restrictions. Information in Research Reports may not be suitable or appropriate for Canadian investors.

For residents of Chile: S&P Capital IQ shall not be acting as an Intermediary of any securities referred to in a Research Report. S&P Capital IQ (and its affiliates) is not registered with, and such securities may not be registered in the Securities Registry maintained by the Superintendencia de Valores y Seguros de Chile (Chilean Securities and Insurance Superintendence or "SVS") pursuant to the Chilean Securities Market Law 18045. Accordingly, investment research presented in a Research Report is not intended to constitute a public or private offer of securities in Chile within the meaning of Article 4 of the Chilean Securities Market Law 18045, as amended and restated, and supplemental rules enacted thereunder.

For residents of Colombia: This information and/or information contained in Research Reports is not intended or should not be construed as constituting information delivery to the Colombian Securities Market under Colombian Law.

For residents of Czech Republic: The Intermediary, and not S&P Capital IQ, is solely responsible for complying with licensing requirements under the Capital Markets Act (Act No. 256/2004 Coll., as amended), implementing Directive 2004/39/EC of the European Parliament and of the Council of 21 April, 2004 on markets in financial instruments amending Council Directives 85/611/EEC and 93/6/EEC and Directive 2000/12/EC of the European Parliament and of the Council and repealing Council Directive 93/22/EEC and its implementing directives, and Directive 2003/125/EC implementing Directive 2003/6/EC as regards the fair presentation of investment recommendations and the disclosure of conflicts of interest; and the Civil Code (Act No. 40/1964 Coll., as amended) as regards the distance financial contract regulation

protecting the consumers.

For residents of Dubai (DIFC): The information contained in Research Reports distributed by S&P Capital IQ is intended for investors who are "professional clients", as defined in Rule 2.3.2(2) of the Conduct of Business Module (COB) of the DFSA Rulebook.

For residents of the European Economic Area (EEA): Research Reports have been approved for distribution in the EEA listed here: Austria; Belgium; Bulgaria; Cyprus; Czech Republic (see further disclosure above); Denmark; Estonia; Finland; France (see further disclosure below); Germany; Gibraltar; Greece; Hungary (see further disclosure below); Iceland; Ireland; Italy; Latvia; Liechtenstein; Lithuania; Luxembourg; Malta (see further disclosure below); Netherlands; Norway; Poland; Portugal; Romania; Slovakia (see further disclosure below); Slovenia; Spain (see further disclosure below); Sweden and United Kingdom, as investment research by MHFRE, which is authorized and regulated by the Financial Conduct Authority in the UK. S&P Capital IQ's Stock Reports are to be read in conjunction with "Your Guide to S&P Capital IQ's Stock Reports" which can be found at: www.spcapitaliq.com/stockreportguide.

More information about the written criteria and methodologies for the generation of Research Reports and historical information for Research Reports for the past 12 months are available by contacting S&P Capital IQ Client Services Department at 800-523-4534 or via e-mail at: clientsupport@standardandpoors.com or clientsupport@sandp.com.

For residents of Guernsey, Isle of Man and Jersey: The Research Reports provided by S&P Capital IQ serve to assist the Intermediary in determining the advice it provides to its clients, but are not intended as advice to any of the Intermediary's clients, and the Intermediary, and not S&P Capital IQ, will be solely responsible for the provision of investment advice to the client. Independent investment advice should be sought by persons in their capacity as investors or potential investors and the Intermediary will be solely responsible for complying with any applicable regulatory obligations relating to the distribution of investment research.

For residents of France: The Intermediary, and not S&P Capital IQ, is solely responsible for complying with the rules related to the distribution of investment recommendations as specified in the Financial Code and the Autorité des Marchés Financiers rule book.

For residents of Hong Kong: Information in the Research Reports shall not be construed to imply any relationship, advisory or otherwise, between S&P and the recipient user of the research report unless expressly agreed by S&P Capital IQ. S&P Capital IQ is not acting nor should it be deemed to be acting, as a "fiduciary" or as an "investment manager" or "investment advisor" to any recipient of this information unless expressly agreed by S&P Capital IQ. The Distributor of the Research Reports will be solely responsible for describing its role to its clients with respect to the distribution of S&P Capital IQ's Research Reports.

Please contact via e-mail at clientsupport@standardandpoors.com or clientsupport@sandp.com if you have any queries on or any matters arising from or in connection with this document.

For residents of Hungary: The Intermediary, and not S&P Capital IQ, is solely responsible for complying with the rules related to data protection requirements as set out in Act CXII of 2011 on the Right of Informational Self-Determination and on Freedom of information; and with Act CLV. of 1997 on Consumer Protection and with Act CXXXVIII of 2007 on Investment services.

For residents of India: Residents of India should consult their financial and legal advisers regarding the suitability of any of S&P Capital IQ's services and products. S&P Capital IQ does not intend to utilize the Research Report service to invite or carry out any business activities with S&P Capital IQ. Research Reports provided by S&P Capital IQ serve to assist the Intermediary in determining the advice it provides to its clients, but are not intended as advice to the Intermediary and to any of the Intermediary's clients and the Intermediary will be solely responsible for the provision of investment advice to the client.

For residents of Indonesia: Research Reports do not constitute an offering document and it should not be construed as an offer of securities in Indonesia, and any such securities will only be offered or sold through a financial institution.

For residents of Israel: Research reports are intended only for distribution to "Qualified Investors", as defined in the Schedule to Israel's Regulation of Investment Advice, Investment Marketing and Portfolio Management Law of 1995. All other persons who are not Qualified Investors under Israeli law should seek additional investment advice from their financial advisers. The relevant analyst declares that the views expressed in a particular Research Report faithfully reflect the analyst's personal views regarding the securities under review and the issuer of the securities.

For residents of Japan: Research Reports are intended only for distribution to "Asset Management Firms".

For residents of Kazakhstan: The distribution to specific persons in Kazakhstan is the sole responsibility of the Distributor and the Distributor, and not S&P Capital IQ, is responsible for complying with all local regulations, including but not limited to advertising requirements related to public solicitation.

For residents of Malta: The Distributor of Research Reports in Malta, is solely responsible for ensuring that the investment research produced by S&P Capital IQ and proposed to be disseminated in or from within Malta is reviewed for compliance with the investment services rules issued by the Malta Financial Services Authority in terms of the Investment Services Act, Cap 370 of the laws of Malta.

For residents of Mexico: S&P Capital IQ is not regulated or supervised by the Mexican National Banking and Securities Commission ("CNBV"). S&P Capital IQ has a licensed rating agency affiliate in Mexico (Standard & Poor's, S.A. De C.V.), of which S&P maintains firewalls and seeks to avoid conflicts of interest, pursuant to approved policies. Research Reports on securities that are not registered with the National Securities Registry maintained by the Mexican National Securities Registry are intended only for distribution to qualified, institutional investors or to any other investors to whom distribution of the S&P Research is permissible under Mexican law.

For residents of Monaco: The Intermediary, and not S&P Capital IQ, will be solely responsible for providing copies of S&P Capital IQ Research Reports to the appropriate Monegasque regulator prior to distributing to its clients.

For residents of Morocco: Research Reports are intended for distribution only to professional investors.

For residents of Peru: S&P Capital IQ's Research Reports shall not, under any circumstances, be considered an invitation to take deposits or funds from the public, under any mechanism, or to carry on any activities that may be prohibited by Peruvian law. The Intermediary also agrees that the use of S&P Capital IQ's Research Reports shall not be used by Intermediary to solicit an investment in the securities that are the subject of the Research Report in any way that may be prohibited by Peruvian law.

For residents of Qatar: The Distributor, and not S&P Capital IQ, is responsible for complying with all relevant licensing requirements as set forth by the Qatar Financial Markets Authority or the Qatar Central Bank, and with all relevant rules and regulations set out in the Qatar Financial Markets Authority's rule book, including third party branded investment research distribution of securities that are admitted for trading on a Qatari securities exchange (Admitted Securities).

For residents of Russia: Research Reports on financial instruments are intended for "qualified investors", as defined in the Securities market law of the Russian Federation dated 22 April 1996, as amended, only.

For residents of The Kingdom of Saudi Arabia: S&P Capital IQ and its affiliates do not distribute Research Reports in the Kingdom of Saudi Arabia. Residents of Saudi Arabia should be aware that the Distributor of S&P Capital IQ's Research Reports may not be permitted to distribute investment research either: (i) from a permanent place of business in or otherwise within the territory of the Kingdom of Saudi Arabia; or (ii) to an investor in the Kingdom of Saudi Arabia unless that investor is a Capital Market Authority authorized investor or the Saudi Arabian Monetary Agency.

When a Distributor disseminates S&P Capital IQ's Research Reports in the Kingdom of Saudi Arabia, the Distributor, and not S&P Capital IQ, is solely responsible for approving the contents of Research Reports and complying with licensing requirements and authorizations of the Saudi Arabian Capital Market Authority's ("CMA"), including CMA's Authorized Persons Regulations concerning securities advertisements.

S&P does not conduct a securities business in the Kingdom of Saudi Arabia and the Distributor, and not S&P Capital IQ, assumes all responsibilities and liabilities for distributing Research Reports in the Kingdom of Saudi Arabia. **Research Reports are not intended to be investment advice and do not constitute any form of invitation or inducement by S&P Capital IQ to engage in an investment activity in the Kingdom of Saudi Arabia.** S&P Capital IQ does not communicate directly with a Distributor's customers and a Distributor's customers should not contact S&P Capital IQ directly regarding any information or data provided in Research Reports.

For residents of Singapore: Recipients of the Research reports in Singapore should contact the Distributor of the Research Reports in respect to any matters arising from, or in connection with, the analysis of the report. The Distributor accepts all legal responsibility for the contents of the Research Reports. When reports are distributed by Intermediaries in Singapore, the Intermediary, and not S&P Capital IQ, is solely responsible for ensuring that the recipients of the Research Reports understand the information contained in the Research Reports and that such information is suitable

based on the customer's profile and investment objectives.

For residents of Slovak Republic: The Intermediary, and not S&P Capital IQ, is solely responsible for complying with the rules related to the Slovak Securities Act (Act No. 566/2001 Coll., as amended), implementing Directive 2004/39/EC of the European Parliament and of the Council of 21 April 2004 on markets in financial instruments amending Council Directives 85/611/EEC and 93/6/EEC and Directive 2000/12/EC of the European Parliament and of the Council and repealing Council Directive 93/22/EEC and its implementing directives, and Directive 2003/125/EC implementing Directive 2003/6/EC as regards the fair presentation of investment recommendations and the disclosure of conflicts of interest; and with the Slovak Act on Consumer Protection in Distance Financial Services Contracts (Act No. 266/2005 Coll., as amended).

For residents of Spain: Certain of S&P Capital IQ's equity Research Reports may be considered to be marketing communications for purposes of Spanish law.

For residents of the United Arab Emirates (UAE): S&P Capital IQ and its affiliates neither undertake banking, financial, or investment consultations business in or into the UAE within the meaning of the Central Bank Board of Directors' Resolution No. 164/8/94 regarding the regulations for investment companies nor provides financial analysis or consultation services in or into the UAE within the meaning of UAE SECURITIES AND COMMODITIES AUTHORITY DECISION NO. 48/R OF 2008 concerning financial consultation and financial analysis.

Investment research distributed by S&P Capital IQ and its affiliates is not intended to amount to an offer of securities within the meaning of DIFC Law NO. 12 OF 2004 (the DIFC Markets Law) or the equivalent laws, rules and regulations made by the Central Bank of the UAE and their Emirates Securities and Commodities Authority. Neither the Dubai Financial Services Authority, the UAE Securities nor Commodities Authority of the Central Bank of the UAE has reviewed or verified any of the information provided in a Research Report or through any service provided by S&P Capital IQ or its affiliates, or has any responsibility for it.

If a recipient of Research Report does not understand any of the contents of the Research Report, the recipient should contact a financial advisor. Users of extracts of investment Research Reports should be aware that if they are distributed in the UAE by an Intermediary, the Intermediary is solely responsible for the distribution and contents of the investment research in the UAE.

For residents of Uruguay: S&P Capital IQ or its affiliates are not, individually a risk assessment entity registered with the Central Bank of Uruguay, and S&P Capital IQ's Research Reports do not constitute a risk assessment. Investment research presented in a Research Report is not intended to constitute a public or private offer of securities in Uruguay. S&P Capital IQ's Research Reports are not intended for worldwide distribution, as such, and are not published to Uruguayan clients in Spanish.

For residents of Venezuela: Research Reports can only be distributed in Venezuela by an investment advisor, duly licensed under Venezuelan law. The Distributor of the Research Reports, and not S&P Capital IQ, is solely responsible for complying with licensing requirements.

Copyright © 2016 Standard & Poor's Financial Services LLC. All rights reserved. STANDARD & POOR'S, S&P, S&P 500, S&P EUROPE 350 and STARS are registered trademarks of Standard & Poor's Financial Services LLC. S&P CAPITAL IQ is a trademark of Standard & Poor's Financial Services LLC.